Non-Surgical BCIs: Subsense CEO Tetiana Aleksandrova on Neurodegeneration and Cognitive Enhancement

Tetiana Aleksandrova, CEO and founder of Subsense, explains how her team is building a nanoparticle-based Brain Computer Interface designed to treat symptoms of neurological disorders while unlocking new possibilities for human cognition.Episode Breakdown:00:00 – Opening and long-term vision for merging humans with technology01:10 – Guest introduction: Tetiana Aleksandrova, CEO and founder of Subsense02:01 – Personal journey: from chemistry to economics to serial BCI entrepreneur03:38 – Lessons learned from her first EEG-based BCI company05:25 – Why Subsense pivoted to nanoparticle-based BCIs06:52 – The problem with current treatments for neurodegenerative diseases07:40 – Non-surgical alternatives to deep brain stimulation09:35 – Nanoparticles as antennas for brain signals12:20 – Duration, delivery methods, and safety of nanoparticles13:04 – First clinical targets: Parkinson’s and epilepsy14:50 – Why non-surgical BCIs excite clinicians and investors16:05 – Expanding into broader neurological disorders and cognitive enhancement17:02 – Device design and hardware considerations18:19 – Why separate nanoparticles are needed for reading and stimulation20:01 – Collaborations with UC Santa Cruz and ETH Zurich21:08 – Regulatory challenges and breakthrough designation pathway22:21 – How stimulation nanoparticles work in the brain25:01 – Potential beyond medicine: memory, focus, and human performance28:14 – Public demand for cognitive optimization since COVID30:33 – The AI revolution and parallels with the BCI revolution33:01 – Why BCIs could be the next major technological shift34:20 – $17M funding round led by Golden Falcon Capital and Palo Alto lab launch36:45 – Future milestones and how to connect with SubsenseThis podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Are you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to ⁠⁠GrowMyMedtech.com⁠⁠ to book time for a free analysis.Subscribe to our Youtube Channel⁠⁠https://www.youtube.com/channel/UCGpL_rGt1LQJwinMq_K7gfg⁠⁠Subscribe to our LinkedIn Newsletter⁠⁠https://www.stateofmedtechpodcast.com/⁠⁠Follow The State of MedTech onLinkedIn ⁠⁠https://www.linkedin.com/company/thestateofmedtech⁠⁠Instagram ⁠⁠https://www.instagram.com/stateofmedtech/⁠⁠TikTok ⁠⁠https://www.tiktok.com/@stateofmedtech⁠⁠X ⁠⁠https://twitter.com/StateofMedTech⁠⁠Facebook ⁠⁠https://www.facebook.com/stateofmedtech/⁠⁠Follow Omar M. Khateeb onLinkedIn ⁠⁠https://www.linkedin.com/in/okhateeb/⁠⁠Instagram ⁠⁠https://www.instagram.com/omar.m.khateeb/⁠⁠TikTok ⁠⁠https://www.tiktok.com/@omarkhateebofficial⁠⁠X ⁠⁠https://twitter.com/OmarMKhateeb⁠⁠Facebook ⁠⁠https://www.facebook.com/OmarMKhateeb/⁠#BCI #Neurotech #Medtech #HealthcareInnovation #BrainComputerInterface #DigitalHealth #Neuroscience